Prelude Therapeutics (PRLD)
(Delayed Data from NSDQ)
$3.45 USD
-0.15 (-4.17%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $3.41 -0.04 (-1.16%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PRLD 3.45 -0.15(-4.17%)
Will PRLD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PRLD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRLD
New Strong Buy Stocks for January 25th
All You Need to Know About Prelude Therapeutics Incorporated (PRLD) Rating Upgrade to Buy
PRLD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Prelude (PRLD) Collaborates With BeiGene for Oncology Candidate
Is a Surprise Coming for Prelude Therapeutics (PRLD) This Earnings Season?
Wall Street Analysts Predict a 169% Upside in Prelude Therapeutics Incorporated (PRLD): Here's What You Should Know
Other News for PRLD
Wall Street's Top 10 Stock Calls This Week - Saturday, June 22
Buy/Sell: Wall Street's top 10 stock calls this week
Spirit Aero downgraded, Skyworks upgraded: Wall Street's top analyst calls
Prelude Therapeutics just downgraded at Barclays, here's why
Barclays cuts Prelude to underweight, cites lack of near-term catalysts